Tin tức & Cập nhật

Severe COVID-19 rare in PrEP-treated SARDs patients
Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024 bởiStephen Padilla

Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.

Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024
Adalimumab concentrations negatively linked to inflammatory markers in RA
Adalimumab concentrations negatively linked to inflammatory markers in RA
08 Mar 2024

A negative association exists between adalimumab (ADA) concentrations and markers of inflammatory disease activity in rheumatoid arthritis (RA), including interleukin 6 (IL-6), reveals a study. Notably, ADA concentrations from 5 to 7 mg/L over the dose interval seem to contribute to better disease control.

Adalimumab concentrations negatively linked to inflammatory markers in RA
08 Mar 2024
High CRP level tied to earlier death in ILD
High CRP level tied to earlier death in ILD
07 Mar 2024
Abatacept may mitigate rheumatoid arthritis development in at-risk individuals
Abatacept may mitigate rheumatoid arthritis development in at-risk individuals
23 Feb 2024
Is BASDAI a responsive instrument in PsA?
Is BASDAI a responsive instrument in PsA?
13 Feb 2024

Use of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as an instrument in psoriatic arthritis (PsA) demonstrates “reasonable” responsiveness but falls short of distinguishing peripheral PsA from axial (ax)PsA, according to a recent study.

Is BASDAI a responsive instrument in PsA?
13 Feb 2024